srx acquisition target, page-6

Lopez

Yes alot more as I think bta shareholders are hanging out for much more than what it's currently worth, including moi.

It's an interesting idea though to get some of these 'soon to break through to the big time' aussie biotechs to merge rather than be taken over. Get some size and then possibly better recognition from bigger fund managers, be more diversified etc. I guess the downside might be a lack of focus.

What aussie biotech would fit well with srx? Not sure bta would, but other cancer related biotechs might fit well?

cheers